LINE-1 as a therapeutic target for castration-resistant prostate cancer.

@article{Houd2018LINE1AA,
  title={LINE-1 as a therapeutic target for castration-resistant prostate cancer.},
  author={N. Hou{\'e}d{\'e} and P. Piazza and P. Pourquier},
  journal={Frontiers in bioscience},
  year={2018},
  volume={23},
  pages={
          1292-1309
        }
}
Prostate cancer is the third leading cause of death by cancer in men. Surgery or hormone deprivation usually contains the progression of the local forms of the disease. In metastatic situations, chemotherapy or second generation hormone therapies are used with an overall survival that never exceeds 36 months when tumors become resistant to castration. In the search for new alternatives, clinical trials with various classes of anticancer drugs have been performed, including chemotherapies… Expand
4 Citations

References

SHOWING 1-10 OF 141 REFERENCES
Progress of molecular targeted therapies for prostate cancers.
  • 48
A comprehensive review of immunotherapies in prostate cancer.
  • 38
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
  • 177
Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
  • 24
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
  • 1,719
Immunotherapy for prostate cancer: False promises or true hope?
  • 17
Enzalutamide in metastatic prostate cancer before chemotherapy.
  • 1,848
  • PDF
...
1
2
3
4
5
...